Cleo Diagnostics (ASX:COV) Research & Development: A$2.28 Mil (TTM As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.48
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Research & Development?

Cleo Diagnostics ASX:COV 17 Research & Development is A$2.28 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cleo Diagnostics's Research & Development for the six months ended in Dec. 2025 was A$2.28 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.28 Mil.

Cleo Diagnostics  (ASX:COV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cleo Diagnostics Research & Development Related Terms

Cleo Diagnostics Research & Development Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Research & Development Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Research & Development
0.00 0.00 0.00

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 0.26 0.00 1.36 0.00 2.28
ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$2.28 Mil mean?
Cleo Diagnostics (ASX:COV) has a Research & Development of A$2.28 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Research & Development too high?
Cleo Diagnostics' current Research & Development is A$2.28 Mil. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Research & Development compare to ABT and SYK?
Cleo Diagnostics' Research & Development of A$2.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Research & Development is A$2.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Research & Development of A$2.28 Mil. The current Research & Development is A$2.28 Mil. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Research & Development is A$2.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price